Price
$23.72+7.03%1Y
1M-7.18%1Y+7.03%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Average5/10
Value49
Quality70
Momentum23
Growth38
P/E (TTM)18.3
Market Cap$143.68B
1Y Return+7.03%
5Y Return-20.96%
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $14.85B (-13.11%)
●Oncology Biosimilars grew +54.92% YoY●Paxlovid EUALabeled -62.12% YoY
SegmentLatestQoQYoY
- Eliquis$2.17B+7.49%+12.64%
- Prevnar Prevenar Family$1.69B-2.99%+1.81%
- Vyndaqel$1.60B+0.69%+7.81%
- Ibrance$1.01B-4.64%+3.17%
- All Other Hospital And Biosimilars$953.0M-+5.77%
- Other Primary Care Products$654.0M-9.29%+7.39%
- Padcev$591.0M+27.37%+38.73%
- Other Specialty Care$579.0M+42.26%+19.14%
- Xtandi$444.0M-23.18%-3.06%
- Oncology Biosimilars$409.0M+29.84%+54.92%
- Royalty$396.0M-9.17%+28.57%
- Other Oncology Products$376.0M+38.24%-0.27%
- Nurtec ODTVydura$353.0M-14.32%+42.34%
- Lorbrena$305.0M+13.81%+37.39%
- Pfizer Centre One$289.0M-15.99%+5.86%
- Comirnaty$232.0M-79.84%-58.94%
- Inlyta$214.0M-5.31%-2.28%
- Sulperazon$199.0M+29.22%+21.34%
- Adcetris$190.0M-11.63%-12.84%
- Paxlovid EUALabeled$186.0M-84.82%-62.12%
- Inflectra$182.0M+5.20%+18.95%
- Abrysvo$180.0M-35.48%+37.40%
- Xeljanz$180.0M-42.49%+40.63%
- Braftovi Mektovi$174.0M-13.86%+27.94%
- Zavicefta$150.0M-5.06%+11.11%
- Enbrel$138.0M-10.39%-1.43%
- Bosulif$129.0M-14.00%-14.57%
- Octagam$122.0M+7.96%+38.64%
- Tukysa$122.0M+10.91%+19.61%
- Zithromax Zmax$112.0M+53.42%-29.11%
- Orgovyx$109.0M-2.68%+43.42%
- Genotropin$93.0M-27.34%-2.11%
- FSMEIMMUNTico Vac$81.0M-19.00%+28.57%
- Elrexfio$80.0M-5.88%+33.33%
- Cibinqo$76.0M-3.80%+31.03%
- Talzenna$50.0M+6.38%+25.00%
- Tivdak$33.0M-10.81%0.00%
- All Other Inflammationand Immunology Products---
- All Other Internal Medicine---
- All Other Rare Disease Products---
- Aromasin---
- BMP2---
- Bavencio Alliance Revenues---
- Bene FIX---
- Besponsa---
- Bicillin---
- Braftovi---
- Chantix Champix---
- Cresemba---
- Fragmin---
- IVIg Products---
- Ig Portfolio Products---
- Medrol---
- Mektovi---
- Nimenrix---
- Other Antiinfectives---
- Other Hospital---
- Other Hospital Products---
- Other Vaccines Products---
- Oxbryta---
- Paxlovid---
- Paxlovid NDALabeled USStrategic National Stockpile---
- Pfizer Ignite---
- Premarin Family---
- Re Facto Af Xyntha---
- Retacrit---
- Ruxience---
- Somavert---
- Sutent---
- Total Alliance Biopharmaceuticals---
- Total Biosimilars---
- Total Sterile Injectable Pharmaceuticals---
- Toviaz---
- Trazimera---
- Trumenba---
- Vfend---
- Xalkori---
- Xtandi Alliance Revenues---
- Zirabev---